- Home
- PD vs AVIR Comparison
PD vs AVIR Comparison
Compare PD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | AVIR |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | 1155 | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.7M | 434.5M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PD | AVIR |
|---|---|---|
| Price | $6.87 | $4.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $12.63 | $10.00 |
| AVG Volume (30 Days) | ★ 1.9M | 284.9K |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | 3.00 |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $492,546,000.00 | $351,367,000.00 |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | $3.74 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.70 | $2.78 |
| 52 Week High | $17.45 | $6.45 |
Technical Indicators
Market Signals| Indicator | PD | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 25.08 |
| Support Level | $6.01 | $3.32 |
| Resistance Level | $7.91 | $4.34 |
| Average True Range (ATR) | 0.39 | 0.26 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 37.55 | 6.70 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.